425 related articles for article (PubMed ID: 27515872)
1. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Efficacy of
Fuladi S; Emami SA; Mohammadpour AH; Karimani A; Manteghi AA; Sahebkar A
Curr Rev Clin Exp Pharmacol; 2021; 16(2):191-196. PubMed ID: 32282308
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled trial on the effect of Ashwagandha (Withania somnifera dunal.) root extract in improving cardiorespiratory endurance and recovery in healthy athletic adults.
Tiwari S; Gupta SK; Pathak AK
J Ethnopharmacol; 2021 May; 272():113929. PubMed ID: 33600918
[TBL] [Abstract][Full Text] [Related]
4. Influence of Withania somnifera on obsessive compulsive disorder in mice.
Kaurav BP; Wanjari MM; Chandekar A; Chauhan NS; Upmanyu N
Asian Pac J Trop Med; 2012 May; 5(5):380-4. PubMed ID: 22546655
[TBL] [Abstract][Full Text] [Related]
5. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
[TBL] [Abstract][Full Text] [Related]
6. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study.
Pakseresht S; Boostani H; Sayyah M
J Complement Integr Med; 2011 Oct; 8():. PubMed ID: 22718671
[TBL] [Abstract][Full Text] [Related]
7. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
8. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
[TBL] [Abstract][Full Text] [Related]
9. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
[TBL] [Abstract][Full Text] [Related]
10. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
12. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions.
Choudhary D; Bhattacharyya S; Bose S
J Diet Suppl; 2017 Nov; 14(6):599-612. PubMed ID: 28471731
[TBL] [Abstract][Full Text] [Related]
14. A Standardized
Majeed M; Nagabhushanam K; Murali A; Vishwanathan DT; Mamidala RV; Mundkur L
J Integr Complement Med; 2024 May; 30(5):459-468. PubMed ID: 37878284
[No Abstract] [Full Text] [Related]
15. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
Yousefzadeh F; Sahebolzamani E; Sadri A; Mortezaei A; Aqamolaei A; Mortazavi SH; Shalbafan MR; Ghaffari S; Alikhani R; Mousavi SB; Naderi S; Shamabadi A; Jalilevand S; Akhondzadeh S
Int Clin Psychopharmacol; 2020 Sep; 35(5):254-262. PubMed ID: 32541380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial.
Sharma AK; Basu I; Singh S
J Altern Complement Med; 2018 Mar; 24(3):243-248. PubMed ID: 28829155
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
18. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.
Chengappa KNR; Brar JS; Gannon JM; Schlicht PJ
J Clin Psychiatry; 2018 Jul; 79(5):. PubMed ID: 29995356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
